| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 700% | Wedbush | $11 → $9 | Maintains | Outperform |
| 10/23/2023 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 10/19/2023 | — | TD Cowen | Downgrades | Outperform → Market Perform | |
| 08/16/2023 | 700% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 08/03/2023 | 1144.44% | Needham | → $14 | Reiterates | → Buy |
| 08/03/2023 | 877.78% | Wedbush | → $11 | Reiterates | Outperform → Outperform |
| 05/11/2023 | 1144.44% | Needham | → $14 | Reiterates | Buy → Buy |
| 04/19/2023 | 1144.44% | Needham | → $14 | Reiterates | → Buy |
| 03/24/2023 | 522.22% | JMP Securities | → $7 | Reiterates | → Market Outperform |
| 03/23/2023 | 1144.44% | Needham | → $14 | Reiterates | → Buy |
| 03/06/2023 | 98.22% | JMP Securities | $7 → $2.23 | Maintains | Market Outperform |
| 02/24/2023 | 1233.33% | Wedbush | $24 → $15 | Maintains | Outperform |
| 02/24/2023 | 1144.44% | Needham | $23 → $14 | Maintains | Buy |
| 01/19/2023 | 522.22% | JMP Securities | $11 → $7 | Maintains | Market Outperform |
| 11/08/2022 | 700% | Canaccord Genuity | → $9 | Initiates Coverage On | → Buy |
| 08/08/2022 | 877.78% | JMP Securities | $10 → $11 | Maintains | Market Outperform |
| 08/05/2022 | 1944.44% | Needham | $27 → $23 | Maintains | Buy |
| 12/15/2021 | 788.89% | JMP Securities | $40 → $10 | Maintains | Market Outperform |
| 12/15/2021 | 2300% | Needham | $50 → $27 | Maintains | Buy |
| 12/14/2021 | 2655.56% | Wedbush | $36 → $31 | Maintains | Outperform |
| 07/14/2021 | 3100% | Wedbush | $40 → $36 | Maintains | Outperform |
| 06/08/2021 | 3455.56% | JMP Securities | → $40 | Initiates Coverage On | → Market Outperform |
| 02/24/2021 | 3900% | William Blair | → $45 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 4344.44% | Needham | → $50 | Initiates Coverage On | → Buy |
| 07/07/2020 | 2655.56% | Wedbush | → $31 | Initiates Coverage On | → Outperform |
| 07/07/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/07/2020 | 2388.89% | JP Morgan | → $28 | Initiates Coverage On | → Overweight |
| 07/07/2020 | 3277.78% | Jefferies | → $38 | Initiates Coverage On | → Buy |
What is the target price for Generation Bio (GBIO)?
The latest price target for Generation Bio (NASDAQ: GBIO) was reported by Wedbush on November 10, 2023. The analyst firm set a price target for $9.00 expecting GBIO to rise to within 12 months (a possible 700.00% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Generation Bio (GBIO)?
The latest analyst rating for Generation Bio (NASDAQ: GBIO) was provided by Wedbush, and Generation Bio maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Generation Bio (GBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Generation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Generation Bio was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Generation Bio (GBIO) correct?
While ratings are subjective and will change, the latest Generation Bio (GBIO) rating was a maintained with a price target of $11.00 to $9.00. The current price Generation Bio (GBIO) is trading at is $1.13, which is out of the analyst's predicted range.